SINCE 2005
We are devoted to developing a novel type of nanomedicine for the therapy and diagnosis of obstinate diseases by using stimuli-sensitive materials, engineered extracellular vesicles, and living biotherapeutics.
Research interests
Stimuli-sensitive nanomedicine
Stimuli-responsive nanomedicines are designed to respond to specific microenvironments or internal/external stimuli for spatiotemporal controlling of the action. We focus on developing stimuli-responsive nanomedicine based on organic/inorganic materials for targeted imaging and therapy of various intractable diseases by adapting enhanced chemotherapy, photo/sonodynamic therapy, and image-guided therapy.
Immunotherapeutic nanomedicine
Immunotherapy, which uses the patient’s immune system to fight tumors, shows superior clinical results to conventional treatment. However, the proportion of patients responding to immunotherapy remains low or moderate. We explore ways to control the immune system spatiotemporally to maximize the therapeutic effect by applying nanomedicine.
Engineered extracellular vesicles
Since exosomes contain nucleic acids, lipids and proteins, exosomes have emerged as a cell-free therapeutic agent for treating various pathologies such as inflammatory diseases, liver fibrosis, and cancer. We focus on the development of engineered exosomes through modification of EV surface and content to enhance therapeutic efficacy.
Engineered living biotherapeutics
A microbiome is a community of microorganisms interacting with host health and disease, and it has recently been highlighted as a key determinant of many aspects of physiological functions. We develop ways to modulate the microbiome and its influence by modifying the in vivo fate and function of living biotherapeutics.
Recent publications
Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury
Kim SH, Kim CH, Lee CH, Lee J, Kang H, Cho S, Jang WH, Park M, Ha M, Kim J, Um W, Kwon S, Lee S, Kim JW, Chung CH, Park JH*
Biomaterials 2025 318:123165 (IF: 12.8, JCR 3.3%)
Han KH, Kim CH, Kim SH, Lee CH, Park M, Bui VD, Duong VH, Kwon S, Ha M, Kang H, Park JH*
Shin S, Ko H, Kim CH, Yoon BK, Son S, Lee JA, Shin JM, Lee J, Song SH, Joshua A.J*, Park JH*
Nature Materials 2023 22:656-665 (IF: 41.2, JCR 0.3%)